Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation

International Journal of Clinical Pharmacology and Therapeutics

Volumn 53, Issue 3, 2015, Pages 211-219

  Messori, Andrea ^a   Fadda, Valeria ^a   Maratea, Dario ^a   Trippoli, Sabrina ^a   Marinai, Claudio ^a  

^a ESTAV Toscana Centro   (Italy)

Author keywords

Anticoagulants ; Apixaban ; Atrial fibrilation; Dabigatran ; Edoxaban ; Orthopedic surgery ; Rivaroxaban ; Stroke ; Thromboprophylaxis ; Venous thromboembolism ; Warfarin

Indexed keywords

APIXABAN; DABIGATRAN; EDOXABAN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

ARTICLE; ATRIAL FIBRILLATION; ATTRIBUTABLE RISK; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; META ANALYSIS (TOPIC); NONVALVULAR ATRIAL FIBRILLATION; ORTHOPEDIC SURGERY; SYSTEMATIC REVIEW (TOPIC); VENOUS THROMBOEMBOLISM; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING; COMPLICATION; DRUG EFFECTS; META ANALYSIS; ORAL DRUG ADMINISTRATION; PATIENT SAFETY; RISK ASSESSMENT; STROKE; THERAPEUTIC EQUIVALENCE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION; HUMANS; MORPHOLINES; ORTHOPEDIC PROCEDURES; PATIENT SAFETY; PYRAZOLES; PYRIDINES; PYRIDONES; RISK ASSESSMENT; STROKE; THERAPEUTIC EQUIVALENCY; THIAZOLES; THIOPHENES; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84938375387     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202183     Document Type: Article

References (29)

1. Maratea D, Fadda V, Trippoli S, Gatto R, De Rosa M, Marinai C, Messori A. Biological drugs for inducing remission in patients with ulcerative colitis: determining statistical equivalence according to evidence-based methods. Aliment Pharmacol Ther. 2014; 39: 1242-1244. CrossRef PubMed
2. Messori A, Maratea D, Fadda V, Trippoli S, Marinai C. Biological drugs for inducing remission in patients with Crohn's disease: determining statistical equivalence according to evidence-based methods. Arch Med Sci. 2014 (in press), preprint available at http://www.osservatorioinnovazione. net/papers/arch-med-sci-2014.pdf
3. Messori A, Fadda V, Maratea D, Trippoli S, Marinai C. Testing the therapeutic equivalence of alogliptin, linagliptin, saxagliptin, sitagliptin or vildagliptin as monotherapy or in combination with metformin in patients with type 2 diabetes. Diabetes Ther. 2014; 5: 341-344. PubMed
4. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012; 119: 2537-2548. CrossRef PubMed
5. Messori A, Fadda V, Gatto R, Maratea D, Trippoli S. New oral anticoagulants in acute coronary syndrome: is there any advantage over existing treatments? Int Cardiovasc Res J, 2014 (in press), preprint available at: http://www.osservatorioinnovazione.net/papers/noacs-icvrj-2014.pdf
6. Hay CR. Purchasing factor concentrates in the 21st century through competitive tendering. Haemophilia. 2013; 19: 660-667. CrossRef PubMed
7. Messori A, Fadda V, Maratea D, Gatto R, Trippoli S, De Rosa M, Marinai C. Intravenous proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: determining statistical equivalence according to evidence-based methods. Int J Clin Pharmacol Ther. 2014. in press. http://www.osservatorioinno vazione.net/papers/ iv-ppi-ijcpt2014.pdf.
8. Messori A, Fadda V, Gatto R, Maratea D, Trippoli S. Differentiating between "no proof of difference" and "proof of no difference" for new oral anticoagulants. BMJ. 2014; 348: g1955. PubMed
9. Messori A. PubMed Commons (Comment), Published 2 March 2014, available at http://www. ncbi.nlm.nih.gov/pubmed/24026260#cm2?4?0?2?6?2?6? 0-3154
10. Messori A, Maratea D, Fadda V, Trippoli S. Risk of intracranial haemorrhage in patients with atrial fibrillation treated with novel oral anticoagulants: testing the equivalence margins between dabigratran, rivaroxaban and apixaban. Eur J Clin Pharmacol. 2014; 70: 505-506. CrossRef PubMed
11. Ahn S, Park SH, Lee KH. How to demonstrate similarity by using noninferiority and equivalence statistical testing in radiology research. Radiology. 2013; 267: 328-338. CrossRef PubMed
12. Christensen E. Methodology of superiority vs. equivalence trials and non-inferiority trials. J Hepatol. 2007; 46: 947-954. CrossRef PubMed
13. Tunes da Silva G, Logan BR, Klein JP. Methods for equivalence and noninferiority testing. Biol Blood Marrow Transplant. 2009; 15 (Suppl): 120-127. CrossRef PubMed
14. Norman G, Monteiro S, Salama S. Sample size calculations: should the emperor's clothes be off the peg or made to measure? BMJ. 2012; 345 (aug23 1): e5278. CrossRef PubMed
15. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014; 189: 250-255. CrossRef PubMed
16. Tanaka S, Kinjo Y, Kataoka Y, Yoshimura K, Teramukai S. Statistical issues and recommendations for noninferiority trials in oncology: a systematic review. Clin Cancer Res. 2012; 18: 1837-1847. CrossRef PubMed
17. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997; 50: 683-691. CrossRef PubMed
18. Maratea D, Fadda V, Trippoli S, Messori A. Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants. J Thromb Haemost. 2011; 9: 1868-1870. CrossRef PubMed
19. Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ. RENOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty. A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011; 105: 721-729. CrossRef PubMed
20. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383: 955-962. CrossRef PubMed
21. Fadda V. Meta-analysis on novel oral anticoagulants vs warfarin for stroke prevention: re-expressing the results as risk difference (Comment), PubMed Commons, available at http://www.ncbi.nl? m?.nih.gov/pubmed/24315724#cm24315724-3448
22. Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling RJ, Schmitt J, Zamorano JL. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events - European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2014; 16: 6-14. CrossRef PubMed
23. Wisløff T, Hagen G, Klemp M. Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation. Pharmacoeconomics. 2014; 32: 601-612. CrossRef PubMed
24. Liew A, O'Donnell M, Douketis J. Comparing Mortality in Patients with Atrial Fibrillation who are Receiving a Direct Oral Anticoagulant or Warfarin: A Meta-analysis of Randomized Trials. J Thromb Haemost. 2014; doi: 10.1111/jth.12651, epub ahead of print. CrossRef PubMed
25. Bloom BJ, Filion KB, Atallah R, Eisenberg MJ. Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran. Am J Cardiol. 2014; 113: 1066-1074. CrossRef PubMed
26. Artang R, Rome E, Nielsen JD, Vidaillet HJ. Metaanalysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Am J Cardiol. 2013; 112: 1973-1979. CrossRef PubMed
27. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012; 110: 453-460. CrossRef PubMed
28. Messori A, Fadda V, Maratea D, Trippoli S. Risk of myocardial infarction with oral direct thrombin inhibitors: trial sequential analysis based on two published data sets. Am J Cardiol. 2014; 113: 746-748. PubMed
29. Loke YK, Pradhan S, Yeong JK, Kwok CS. Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. Br J Clin Pharmacol. Epub ahead of print. PubMed